Julia Gregory, the CEO of FivePrime Therapeutics, has resigned and been replaced by company founder and executive chairman Lewis “Rusty” Williams, according to a report by In Vivo, a biotech industry publication. Gregory spent two years at the company, and during her time there, struck a lucrative new partnership with Rockville, MD-based Human Genome Sciences (NASDAQ: [[ticker:HGSI]]). A year ago, in an interview with Xconomy, Gregory described FivePrime as a “biotech CEO’s dream.”
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
